TARS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tarsus Pharmaceuticals is not a strong buy right now for a Beginner with a long-term horizon and $50,000-$100,000 to deploy. The business outlook remains attractive, but the current price action is mixed-to-bearish and there is no proprietary buy signal today. My direct view: wait rather than buy now.
Current price is 60.57, only slightly above the pivot at 60.295, so the stock is sitting near a decision point rather than in a clean uptrend. MACD histogram is negative at -0.0137 and still below zero, which signals weak momentum. RSI_6 at 50.077 is neutral, showing no clear bullish strength. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, indicating the broader trend is still unfavorable. Nearby support is 56.826 and resistance is 63.765, so upside needs a break above resistance before the chart improves materially. The pattern-based read suggests limited near-term upside and mixed short-term performance.
Oppenheimer maintained an Outperform view with a $98 target, and the firm highlights Tarsus as a successful commercial biotech story with XDEMVY as the first and only FDA-approved treatment for Demodex blepharitis. It also noted FY2025 net sales of $451.4M and 2026 guidance of $670M-$700M, which points to strong growth momentum. Mizuho also kept an Outperform rating and raised its target to $101 after Grand Pharma received approval to commercialize TP-03 in Greater China, creating an additional international growth catalyst. Hedge funds are buying aggressively, with buying up 987.14% over the last quarter.
Insiders are selling aggressively, with selling up 1503.33% over the last month, which is a negative signal. The technical trend is still weak, with bearish moving averages and a negative MACD. The open interest put-call ratio of 1.92 suggests the options market is leaning defensive. The stock is also trading below the higher analyst targets, so some of the upside story may already be partially priced in. No recent politician or congress trading activity was found.
Latest quarter financials were not provided, so I cannot assess the most recent quarter directly. However, the available company commentary shows strong top-line growth momentum: FY2025 net sales reached $451.4M and 2026 guidance is $670M-$700M. That indicates a continuing growth trajectory for the latest reported full-year period, consistent with a commercial-stage biotech expanding from launch into broader adoption.
Analyst sentiment remains positive overall. Oppenheimer initiated coverage with an Outperform rating and a $98 target, though it cut the target from $105. Mizuho kept an Outperform rating and lifted its target to $101 from $100 after a favorable China approval. Wall Street’s pro view is that XDEMVY is building into a durable commercial growth story with expanding market penetration and international opportunity. The con view is that the target was reduced by Oppenheimer and the stock still needs stronger chart confirmation, so valuation and execution risk are still being watched.
